The European Medicines Agency (EMA) receives an application for registration of a drug from the Swiss company Roche for coronavirus. The medicine is intended for the treatment of patients with coronavirus infection from 12 years of age and older.. This was announced on Monday, October 11 by the EMA press service. EMA has begun reviewing an application for marketing authorization for the Ronapreve monoclonal antibody combination. The agency noted that the application for registration was submitted by the Swiss pharmaceutical company Roche. The drug was developed in cooperation with the American manufacturer Regeneron Pharmaceuticals.

It is indicated that the drug can be used by people with a high risk of infection, for example, those who live in a house with an infected person. " Earlier, the pharmaceutical company Roche announced that the cocktail of antibodies reduces the risk of complications or deaths from coronavirus by 70%.. Recall, scientists have found that drugs for Ebola and the Marburg virus were effective in the fight against SARS-CoV-2. News from in Telegram. Subscribe to our channel https: // t. me / korrespondentnet Author: 1.